Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumabJNCI: Journal of the National Cancer InstituteIF02025-12-270PRE
Clinical efficacy and safety of HER2 targeted therapy in patients with metastatic colorectal cancer: A systematic review and meta-analysisCANCER RESEARCHIF16.62024-03-220PRE
ASCL2+tumor cells modulate the response of colorectal cancer to MAPK targeting therapyCANCER RESEARCHIF16.62024-03-220PRE
Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancerCANCER RESEARCHIF16.62024-03-220PRE
YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancerCANCER RESEARCHIF16.62024-03-220PRE
Identification of Colorectal Cancer Cell Stemness from Single-Cell RNA SequencingMOLECULAR CANCER RESEARCHIF4.72023-12-292OA
CD73's Potential as an Immunotherapy Target in Gastrointestinal CancersFRONTIERS IN IMMUNOLOGYIF5.92020-04-1566OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向